Biotech RadarJobs updated

COMPANY

Engrail Therapeutics

HQ: San Diego, CA source · engrail.com ↗ · West Coast

Clinical Phase 2

Engrail Therapeutics is a clinical-stage pharmaceutical company. From company website Source · Oct 12, 2026

Keywords: pharmaceutical therapeutics Generalized Anxiety Disorder Social Anxiety Disorder Major Depressive Disorder General Anxiety Disorder Focal Epilepsy ENX-102 ENX-104 ENX-205 ENX-101

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

8Trials (company is sponsor)

Timeline

  1. Trial start Phase 1: A Study of ENX-104 in Healthy Participants source ↗
  2. Trial start Phase 2: A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder source ↗
  3. Trial start Phase 1: ENX-205 SAD/PET Study in Healthy Adults source ↗
  4. Trial start Phase 1: A PET Study of ENX-104 in Healthy Volunteers source ↗
  5. Trial start Phase 1: ENX-104 MAD Study for Participants With Major Depressive Disorder With Anhedonia (aMDD) source ↗
  6. Trial start Phase 2: A Dose-Response Safety Study of ENX-102 in Patients With GAD source ↗
  7. Trial start Phase 2: ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder source ↗
  8. Trial start Phase 2: ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures source ↗

Clinical trials (lead sponsor) 8

RecordTitlePhaseStatusStartPrimary completion
NCT05749055ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety DisorderPhase 2CompletedJul 3, 2023Sep 18, 2025 (actual)
NCT07253246ENX-205 SAD/PET Study in Healthy AdultsPhase 1CompletedMar 23, 2025May 7, 2026 (actual)
NCT07472361A Study of ENX-104 in Healthy ParticipantsPhase 1CompletedFeb 25, 2026Mar 19, 2026 (actual)
NCT07193563A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety DisorderPhase 2CompletedSep 5, 2025Mar 19, 2026 (actual)
NCT07253324ENX-104 MAD Study for Participants With Major Depressive Disorder With Anhedonia (aMDD)Phase 1CompletedFeb 17, 2025Nov 26, 2025 (actual)
NCT07253272A PET Study of ENX-104 in Healthy VolunteersPhase 1CompletedFeb 24, 2025Sep 2, 2025 (actual)
NCT06653296A Dose-Response Safety Study of ENX-102 in Patients With GADPhase 2CompletedDec 9, 2024Jun 23, 2025 (actual)
NCT05481905ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal SeizuresPhase 2Withdrawn2022-092024-09 (estimated)
Feedback